<DOC>
	<DOCNO>NCT01616875</DOCNO>
	<brief_summary>26 patient invasive primary transitional cell carcinoma bladder receive 4 cycle combination chemotherapy consist Cabazitaxel Cisplatin give intravenously day 1 3 weekly cycle prior radical cystectomy , evaluate overall response rate determine whether approach warrant research phase II/III study.Participation 2 sub study also offer participant . 1 . Contrast Magnetic resonance imaging ( MRI ) scan take baseline cycle 1 cycle 3 . 2 . A pilot sub study involve circulate tumour cell concentration blood sample take baseline , prior cycle chemotherapy prior surgery</brief_summary>
	<brief_title>Bristol Bladder Trial</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Age ≥18 year Histologically confirm primary transitional cell carcinoma ( TCC ) urinary bladder T2 T4 disease , N0 M0 determine computerise tomography ( CT ) image biopsy transurethral resection Eastern Cooperative Oncology Group ( ECOG ) Performance status 0 1 Glomerular filtration rate ( GFR ) ≥60ml/min . Written , inform consent Exclusion Criteria ECOG Performance Status ≥ 2 Lymph node involvement metastatic disease Prior surgery ( except transurethral resection bladder tumour ) , radiation , chemotherapy , anticancer therapy within 4 week prior enrolment Active Grade ≥2 peripheral neuropathy Active secondary cancer History severe hypersensitivity reaction ( ≥Grade 3 ) polysorbate 80 containing drug Other concurrent serious illness medical condition Inadequate organ function evidence peripheral blood count enrolment : Electrocardiogram ( ECG ) evidence uncontrolled cardiac arrhythmia , angina pectoris , and/or hypertension , history congestive heart failure , myocardial infarction within last 6 month . Uncontrolled diabetes mellitus . Active uncontrolled gastrooesophageal reflux disease ( GORD ) . Active infection require systemic antibiotic antifungal medication Participation another clinical trial investigational drug within 30 day prior study enrolment . Concurrent plan treatment strong inhibitor cytochrome P450 3A4/5 . A 1week washout period necessary patient already treatment . Concurrent plan treatment strong inducer cytochrome P450 3A4/5 . A 1week washout period necessary patient already treatment . Contraindications cisplatin . Patient reproductive potential implementing accept effective method contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Bladder cancer</keyword>
	<keyword>Transitional cell carcinoma</keyword>
	<keyword>Urothelial cancer</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Cabazitaxel</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Neo adjuvant chemotherapy</keyword>
</DOC>